Diclofensine
Discover related
2 sources
How the databases line up — = agree, ≈ partial, ≠ differ. In lists, shared items appear in every source and unique ones in only one (matched case-insensitively).
Show:
| TripSit | Pharmacology | ||
|---|---|---|---|
| Classification | |||
| Class / category | — | ||
| Also known as | ro8-4650 | — | |
| Safety | |||
| Dose · Oral | |||
| Threshold | 12 mg | — | |
| Light | 30–40 mg | — | |
| Common | 40–60 mg | — | |
| Heavy | 60 mg+ | — | |
| Duration | |||
| Total | 4–6 hours | — | |
| Pharmacology | |||
| Receptor activity | — | Sodium-dependent noradrenaline transporterSodium-dependent serotonin transporterSodium-dependent dopamine transporter | |
TripSit summary
A triple monoamine reuptake inhibitor developed by Hoffman-LaRoche in the 1970s as an antidepressant but discontinued, probably due to high abuse potential. Has not become popular as a recreational drug at this time. Acts as an SNDRI, mostly inhibits dopamine and noradrenaline.
Fact-sheets from PsychonautWiki. Harm-reduction reference only — not medical advice.